Zacks Research Issues Negative Forecast for Glaukos Earnings

Glaukos Corporation (NYSE:GKOS) – Research analysts at Zacks Research cut their Q2 2027 earnings estimates for shares of Glaukos in a note issued to investors on Wednesday, May 20th. Zacks Research analyst Team now anticipates that the medical instruments supplier will earn $0.07 per share for the quarter, down from their prior estimate of $0.09. The consensus estimate for Glaukos’ current full-year earnings is ($0.57) per share. Zacks Research also issued estimates for Glaukos’ Q3 2027 earnings at $0.08 EPS, Q4 2027 earnings at $0.30 EPS, FY2027 earnings at $0.38 EPS, Q1 2028 earnings at $0.16 EPS and FY2028 earnings at $1.56 EPS.

A number of other analysts have also weighed in on GKOS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. Citigroup increased their target price on shares of Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. increased their target price on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Stifel Nicolaus set a $170.00 target price on shares of Glaukos in a research note on Thursday, April 30th. Finally, Wells Fargo & Company increased their target price on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $144.42.

Glaukos Trading Up 2.8%

Shares of NYSE:GKOS opened at $143.82 on Thursday. The company has a 50 day moving average of $119.11 and a 200-day moving average of $112.93. The firm has a market cap of $8.45 billion, a P/E ratio of -43.85 and a beta of 0.94. Glaukos has a twelve month low of $73.16 and a twelve month high of $148.11. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business’s revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.22) EPS.

Insider Activity

In other news, COO Joseph E. Gilliam sold 19,573 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the sale, the chief operating officer owned 73,419 shares in the company, valued at $10,538,563.26. The trade was a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director owned 35,528 shares in the company, valued at $5,000,921.28. This represents a 12.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,930 shares of company stock worth $6,321,363 over the last three months. 5.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Glaukos

Large investors have recently made changes to their positions in the company. First Horizon Corp raised its holdings in shares of Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Glaukos during the fourth quarter valued at approximately $28,000. UMB Bank n.a. raised its holdings in shares of Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 158 shares during the period. Larson Financial Group LLC raised its holdings in shares of Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares during the period. Finally, Parallel Advisors LLC raised its holdings in shares of Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 226 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.